Phaseline

Targets › ADV

ADV: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Infectious disease; next expected readout Mar 2028.

Open in Phaseline: the race on ADV, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Tobias FeuchtingerMultivirus (CMV, EBV, AdV)-specific T cells
Adoptive transfer of multivirus-specific T cells targeting CMV, EBV, and AdV
CMV, EBV, ADVPhase 3AdV InfectionMar 2028

Conditions

AdV Infection (1)

Modalities

–

Companies

Tobias Feuchtinger (1)

Related targets

CMV (1) EBV (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.